Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Phase 3

Completed

• Conditions: Hypotension; Bradycardia
• Interventions: Drug: Remifentanil

• Registration Number: NCT03065309
• Lead Sponsor: Brasilia University Hospital

Brief Summary

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Detailed Description

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Study Timeline

• Study First Submitted: 2017-02-22
• Study First Submitted QC: 2017-02-24
• Study Start: 2017-02-25
• Study First Posted: 2017-02-27
• Primary Completion: 2017-02-28
• Study Completion: 2017-03-01
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-12
• Last Update Posted: 2017-09-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Indication of anesthesia induction

Exclusion Criteria

• Protocol violation
• Monitoring problems

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Single Arm	Remifentanil	Patients will receive bolus dose of remifentanil before intubation

Primary Outcome Measures

Name	Time	Method
hemodynamic stability during rapid sequence intubation	from anesthesia induction up to 5 minutes	no bradycardia and no hypotension

Trial Locations

Locations (1)

Hospital das Forças Armadas; 🇧🇷 Brasilia, Distrito Federal, Brazil